Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

Inclusion Criteria

• •1. Female aged at least 18 years old at the time of enrolment
• •2. Oestrogen-receptor positive primary breast cancer in IHC (ER ≥10%)
• •3. HER2-negative primary breast cancer (0, 1+, 2+ FISH negative)
• •4. Metastatic stage with at least one lesion identifiable on the conventional work-up other than a liver lesion
• •5. Patient relapsing under first-line treatment combining a CDK4/6inhibitor and hormone therapy
• •6. Patient having undergone an FDG PET/CT during follow-up of first-line treatment for metastatic tumour revealing the relapse or undergoing a baseline FDG PET/CT seeking the relapse during 2nd line staging (according to the recommendations of the Guide to Correct Use (GBU) for medical imaging tests). A period of 2 to 28 days will be respected between the 2 PET/CT scans (FDG/FES).
• •7. ECOG 0, 1 or 2
• •8. Life expectancy of at least 12 months
• •9. Patient registered with a Social Security scheme
• •10. Patient having signed an informed consent form
• •11. Patient able to follow the study procedures and fill in the quality of life questionnaires